[{"id":"40c7efdf-8bc2-49bd-8de1-be213f764540","acronym":"","url":"https://clinicaltrials.gov/study/NCT06825546","created_at":"2025-02-25T15:16:34.142Z","updated_at":"2025-02-25T15:16:34.142Z","phase":"Phase 2","brief_title":"Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT06825546","lead_sponsor":"Sir Run Run Shaw Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • icaritin (SNG-162)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-13"},{"id":"b4f4bfd5-dca8-47f8-814d-feff46c8295e","acronym":"BESTPOP","url":"https://clinicaltrials.gov/study/NCT05594927","created_at":"2025-03-03T11:03:33.876Z","updated_at":"2025-03-03T11:03:33.876Z","phase":"Phase 3","brief_title":"Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)","source_id_and_acronym":"NCT05594927 - BESTPOP","lead_sponsor":"Beijing Shenogen Biomedical Co., Ltd","biomarkers":" IFNG • TNFA","pipe":"","alterations":" ","tags":["IFNG • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e icaritin (SNG-162)"],"overall_status":"Recruiting","enrollment":" Enrollment 261","initiation":"Initiation: 12/12/2022","start_date":" 12/12/2022","primary_txt":" Primary completion: 08/30/2025","primary_completion_date":" 08/30/2025","study_txt":" Completion: 08/30/2025","study_completion_date":" 08/30/2025","last_update_posted":"2024-08-07"},{"id":"a330ef80-09de-4fe8-8ca5-420057546ca0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06285149","created_at":"2024-02-29T16:32:58.560Z","updated_at":"2024-07-02T16:35:16.964Z","phase":"Phase 2","brief_title":"Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients","source_id_and_acronym":"NCT06285149","lead_sponsor":"Henan Cancer Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e icaritin (SNG-162)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-02-29"},{"id":"a078abaa-f3c6-4b4f-a565-5d79027be5a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03236636","created_at":"2021-01-18T15:59:32.382Z","updated_at":"2024-07-02T16:36:35.563Z","phase":"Phase 3","brief_title":"The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects","source_id_and_acronym":"NCT03236636","lead_sponsor":"Beijing Shenogen Biomedical Co., Ltd","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e icaritin (SNG-162)"],"overall_status":"Recruiting","enrollment":" Enrollment 312","initiation":"Initiation: 09/08/2017","start_date":" 09/08/2017","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2021-01-27"}]